Microfluidic device for obtaining plasma-reagent mixture and method for implementing same
By designing a microfluidic device, using capillary channels and storage containers to achieve uniform mixing of plasma and reagents, the problem of quantitative detection of blood biomarkers in the prior art is solved, and the rapid and accurate detection capabilities at home are achieved, which reduces the laboratory Equipment and professional dependence.
Patent Information
- Application Number
- CN202380030354.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-25
- Filing Date
- 2023-01-12
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to perform the quantitative detection of blood biomarkers quickly and accurately in home or mobile environments, requiring the participation of laboratory equipment and trained personnel, and cannot detect trace amounts of biomarkers.
A microfluidic device is designed, including a blood collection module, capillary channels and storage containers, which separates plasma through semipermeable membranes and specific surfaces, and uses capillary action and actuators to achieve uniform mixing of plasma and reagents to ensure volume control, allowing The production and quantitative detection of plasma-reagent mixtures are performed at home.
Achieve rapid and accurate quantitative detection of blood biomarkers in home or mobile environments, reduce dependence on laboratory equipment and professionals, ensure the reliability and reproducibility of results, and enable detection of microgram-nanogram/ ml of biomarker below.
Smart Images

Figure CN118984734A_ABST
Abstract
Description
[0001] The present invention relates generally to the field of blood testing devices. The present invention more particularly relates to microfluidic devices for obtaining a plasma-reagent mixture and methods of implementing such devices to ultimately allow quantification of target blood biomarkers.
[0002] According to the World Health Organization, in 2019, seven of the ten leading causes of death worldwide were chronic diseases, and the percentage of deaths associated with such diseases has been rising steadily. Chronic diseases are defined as developing diseases that have been going on for months. Many studies have shown that early detection of such diseases increases the patient's chances of survival. For example, in the case of several types of cancer, when the cancer is diagnosed early (stage one or two), the survival rate can be more than three times. Similarly, early detection of markers associated with acute illness or symptoms, as well as pathogens (such as the Covid 19 virus), causative factors associated with Lyme disease or causative factors associated with sepsis or even human immunodeficiency virus (abbreviated as HIV) makes it possible to assess high pathology risks and quickly direct care, which in some cases may need to be immediate and vital in order to promote recovery.
[0003] For this reason, blood biomarkers as biological characteristics are attracting more and more interest as indicators of normal or pathological biological processes. In this regard, each biomarker has specific characteristics that allow it to provide information items related to potential pathophysiological processes and / or data about disease progression. By analogy, biomarkers are to medical practitioners what fingerprints are to police: they are real features that make it possible to identify diseases rather than individuals. Biomarkers are composed of molecules (proteins, hormones, etc.) and cells, and their presence or abnormal concentration in blood, more particularly in plasma, is evidence of the presence of pathology. Plasma is a liquid component of blood without red blood cells, white blood cells, platelets and other contaminants, which constitutes about fifty-five percent of the total blood volume and is estimated to contain at least three hundred proteins.
[0004] Biomarkers may be present in patients with a particular disease and not in individuals who are in good health or affected by other diseases. However, accurate quantification of biomarkers makes it possible to reflect the development of the pathology. For example, the amount of a biomarker may increase or decrease depending on whether the disease is getting worse or improving, or vice versa. Thus, such quantitative indicators make it possible to: - Improve prognosis by delivering complete information to characterize an individual's disease (or presence of a pathogen) and thereby optimize their care; - Adjust the treatment to best suit the patient. In this regard, some people absorb drugs particularly quickly, depending on their metabolism. In such cases, the drug enters the blood faster, its effect increases, and therefore it is necessary to reduce the usually prescribed dose; -Monitoring the effectiveness of treatment. In the case of cancer, for example, cancer cells release various molecules into the bloodstream. If their concentration increases over time, this could mean that the cancer has recurred. Therefore, the quantification of blood biomarkers appears to be an indispensable tool for personalized medicine.
[0005] Conventionally, such quantification is possible by means of conventional, tried and tested blood sample processing. However, such processing requires significant amounts of blood, the involvement of trained personnel and the use of specialized equipment, which results in an expensive and time-consuming technique. In reality, this requires having a prescription from a physician to obtain a blood sample, making an appointment with a nurse or laboratory, assuming that the health care provider and the patient have matching available times, waiting for the blood test to be performed in the laboratory and for the results to be transmitted to the physician, who then interprets them.
[0006] In order to overcome part of the time-consuming steps mentioned above, self-administered blood sample kits are also known on the market, which can be performed by any individual at home using a smaller volume of blood, as disclosed in patent applications US2019 / 0111421, US2014 / 0309557 or WO2014 / 172247A1, which propose devices for collecting and storing or transferring body fluids (in this case blood). However, when in the case of blood samples, such devices require the services of a laboratory to perform the test with specialized equipment and analyze the results by trained personnel.
[0007] Patent application US2017 / 0001192 attempts to partially address these shortcomings by proposing a test device that allows the assessment of biomarkers in body fluids without the aid of one or more external resources (laboratories, trained personnel, etc.). However, this device makes it possible to achieve qualitative results for biomarkers (i.e., the presence or absence of biomarkers) rather than quantitative results for each biomarker. Therefore, this solution requires laboratory analysis in order to quantify the target biomarker and cannot identify proteins present in lower amounts (with an order of magnitude of less than one microgram-nanogram / ml), which may be important markers.
[0008] Documents US2014 / 0309557 and WO2014 / 172247A1 describe devices for sampling, storing and transferring blood samples. Prior to the blood sample, such devices contain anticoagulant additives to ensure that the blood sample is transported to a laboratory responsible for testing the plasma obtained from the blood sample. However, similar to conventional blood sample processing, separation of plasma from other blood components requires the use of specific laboratory equipment, in this case in particular a centrifuge and trained personnel.
[0009] As shown above, only the quantitative results of the biomarkers enable an enhanced monitoring of the patient's health. Therefore, the purpose of the present invention is to overcome the above-mentioned drawbacks and in particular to propose a microfluidic device for obtaining a homogeneous plasma-reagent mixture and a simplified implementation method thereof (in order to finally quantify blood biomarkers directly and quickly at home), which can be used based on a single drop of blood and can be implemented by any user, while ensuring the reliability and reproducibility of the results due to the precise volume analysis / volume control in all steps of the processing of the plasma and reagents used.
[0010] In this regard, a first subject of the invention relates to a microfluidic device for obtaining a homogeneous plasma-reagent mixture, comprising: - Blood collection module; - a first capillary channel having a first end in fluid connection with the collection module; - a fluid storage container connected to the first capillary channel fluid; - a mixing chamber in fluid connection with the second end of the first capillary channel, the mixing chamber being arranged to passively induce a homogeneous mixture of fluids originating from the first capillary and having an outflow opening for the homogeneous mixture; - Means for preventing any fluid from returning to the collection module.
[0011] In order to perform testing at home or on the move, and thus avoid the use of third-party equipment and the need for laboratory testing by trained personnel, this microfluidic device for obtaining a homogeneous plasma-reagent mixture is arranged so that the plasma collection module includes: - a semipermeable membrane arranged to receive a volume of blood and designed to separate blood components by gravity according to their size when said semipermeable membrane is substantially horizontal and thereby retain said components except plasma; - a specific surface, which is arranged between the semipermeable membrane and the first end of the first capillary channel and has hydrophobicity, hydrophilicity and surface tension properties, so as to extract plasma from the semipermeable membrane and cause the plasma to flow in the first capillary channel.
[0012] Furthermore, this microfluidic device for obtaining a homogeneous plasma-reagent mixture is arranged such that: the first capillary channel having a defined dimension between the fluid connection of the storage container with the first capillary channel and the second end of the first capillary channel in order to control the amount of plasma when the first capillary channel is filled with plasma; - the fluid contained in the storage container is a reagent intended to be mixed with the plasma; - The storage container is arranged as follows: ○ The volume of the contained reagent is greater than the sum of the fluid volumes that can be contained in the first capillary channel and the mixing chamber; o having an actuator, the actuator being designed to be controlled after the first capillary channel is filled with plasma When the reagent is forced to flow in the first capillary channel, a uniform plasma-reagent mixture is driven to flow through the outflow port of the mixing chamber.
[0013] In order to optimize capillarity and maximize the movement of plasma from the semipermeable membrane to the first capillary channel, the first end of the first capillary channel may be positioned substantially at the center of the collection module.
[0014] In order to concentrate the blood deposited on the semipermeable membrane and any extension of the blood outside its surface, the collection module of such a device may comprise a membrane holder arranged to concentrate the blood on said semipermeable membrane.
[0015] Advantageously, the specific surface may consist of polymethyl methacrylate, thermoplastic polymers, polyacrylamide, polyurethane, poly(hydroxyethylmethacrylamide) or polyethylene glycol derivatives.
[0016] To optimize the passive and uniform mixture of plasma and reagent flowing in the first capillary channel, the mixing chamber may include a network of channels each arranged in a zigzag, serpentine, or herringbone shape to passively induce the uniform plasma-reagent mixture.
[0017] A second subject of the present invention consists of a method for implementing a microfluidic device according to the present invention for obtaining a homogeneous plasma-reagent mixture. This method comprises the following steps: - a step of depositing blood on the semipermeable membrane of the plasma collection module when the device is positioned so that the semipermeable membrane is horizontal; - a step of filling the first capillary channel with plasma; - after the step of filling the first capillary channel with plasma, a step of controlling the actuator of the storage container to induce the reagent previously contained in the storage container to forcibly flow into the first capillary channel after the mixing chamber is filled; - A step of collecting the homogenous plasma-reagent mixture from its outflow port.
[0018] As an example of an advantageous implementation, the step of filling the first capillary channel with plasma may consist of waiting for a predetermined duration, which is a function of the dimensions of the first capillary channel, once the plasma has flowed into the first capillary channel.
[0019] To produce an analysis of the plasma-reagent mixture, the step of collecting the homogenous plasma-reagent mixture may consist of positioning a reactive strip downstream of the outflow port of the mixing chamber such that the strip collects all or a portion of the homogenous plasma-reagent mixture.
[0020] The disclosure of the invention will now continue with a detailed description of embodiments given below by way of non-limiting illustration, with reference to the accompanying drawings, in which: - Figure 1 A preferred example of implementation of a microfluidic device for obtaining a plasma-reagent mixture according to the present invention is shown; Figure 2 A flow chart representing the steps of a method for implementing the device according to the present invention is shown; - Figures 3 to 7 is a diagrammatic view of a device according to the invention, showing different steps of implementation of said device according to the invention.
[0021] As an introduction, it is important to review the definitions of the following terms: -Hydrophilicity is a term used to characterize the property of molecules resulting from the existence of a strong attraction or affinity between certain molecular groups and water. In other words, it is the affinity of a substance for water or the ability to be wetted by water without being dissolved; - Hydrophobicity is a term used to denote and characterize surfaces that appear to "repel water" or that water appears to have difficulty wetting, which is due in particular to the fact that water molecules are polar and have a preferential attraction to other polar molecules; - Surface tension / surface energy and contact angle: energy per unit surface area, the origin of which is the cohesive forces between identical molecules, which is associated with the interface separating two different media. A representative example of such a quantity is a droplet of liquid deposited on a support / solid: such a droplet forms an angle called the contact angle, which varies as a function of the surface tension of the support / solid. Thus, if there are repulsive forces between the liquid and the solid, a droplet placed on the solid will tend to "reorganize" and tend to adopt a spherical shape, therefore having a "high" contact angle. On the contrary, if there are attractive forces between the liquid and the solid, a droplet placed on the solid will tend to extend, therefore having a "low" contact angle. In the case of a liquid such as water, if the contact angle is greater than zero degrees and less than ninety degrees, the water tends to extend and wet the support / solid: this is then called a wetting or hydrophilic surface. In the case of a contact angle substantially equal to zero degrees, the wetting is complete. Therefore, the higher the contact angle, the less the support / solid can be wetted by water; - Capillary action is a property of fluids that gives them the ability to rise or fall through capillaries / channels, depending on the surface tension of such fluids. The thinner the tube, the greater the distance the liquid travels in the tube; -Plasma is the liquid portion of blood and contains more than ninety percent water. Therefore, plasma is considered to be primarily hydrophilic.
[0022] Figure 1 A preferred example of a microfluidic device 100 for obtaining a uniform plasma-reagent mixture according to the present invention is shown in FIG. The device 100 comprises at least one plasma collection module 110, which is fluidically connected to a first end 120a of a capillary channel 120, which itself is fluidically connected to a storage container 130 of a reagent 103. Within the meaning of the present invention, "reagent" refers to any fluid that makes certain physicochemical parameters of plasma (e.g., pH), such as any fluid that is optimal for the conformation of a protein to be quantified. In addition, such reagents can be selected to control the speed of fluid flow in the device and to limit any nonspecific interactions of the target protein (biomarker) with the semipermeable membrane and the inner wall of the device. As non-limiting examples, it can contain proteins such as BSA (bovine serum albumin), detergents (e.g., Tween 20), saline solutions (e.g., phosphate buffered saline) and / or antibacterial solutions (e.g., sodium azide). This reagent is different from the stabilizers or anticoagulants present in some devices for sampling and transporting blood (such as those described in the aforementioned documents US2014 / 0309557 and WO 2014 / 172247A1), which have the only function of allowing the blood sample to be stored until it reaches the analysis center, and there is no need to move them in the transport device. In addition, the device 100 includes a device 140 for preventing any fluid from returning to the collection module 110, which is positioned upstream of the fluid connection between the storage container 130 and the capillary channel 120. The device 100 also includes a mixing chamber 150 connected to the second end 120b of the capillary channel 120. The device 100 is provided by the method 200 (which is in Figure 2 ) is implemented in order to obtain a homogeneous plasma-reagent mixture 104 based on a minimum amount of blood 101 (more particularly plasma) in the order of ten to one hundred microliters, which mixture 104 ultimately makes it possible to quantify the target blood biomarker by using the test strip directly on site, i.e., for example, at home by the person (usually the patient) from whom the blood sample has been collected, or at the patient's bedside, in an ambulance or in a doctor's consultation room.
[0023] Step 210 of the method 200 comprises supplying plasma 102 to the collection module 110 fluidically connected to the first end 120a of the capillary channel 120, and when the capillary channel 120 is Figure 1When oriented in space as shown in FIG. 1 , the first end 120a is considered to be the upper part of the capillary channel 120, and the second end 120b is considered to be the lower part of the capillary channel 120. Such supply of plasma 102 may require depositing blood in the collection module 110, or may consist of directly depositing plasma in the collection module, when the collection module 110 is arranged to passively separate the plasma 102 from the blood. Figure 3 As shown in FIG. 1 , the plasma 102 can automatically move in the capillary channel 120 by capillary action (this phenomenon is defined above in this specification), and thus vertically (according to Figure 1 In a preferred but non-limiting embodiment, in order to optimize this capillary phenomenon and maximize the related effects, it is preferred to position the first end 120a of the capillary channel 120 substantially at the center of the lower surface of the collection module 110. In a variation, the first end 120a of the capillary channel 120 may be positioned between the outer edge and the center of the lower surface of the collection module 110.
[0024] As described above, using the device 100 according to the invention, plasma 102 can be advantageously separated based on one or more drops of blood 101 collected by the user himself. Such drops 101 can be collected, for example, using a lancet device or any other suitable device that the user can apply to the end of his finger. Once the end of the user's finger has been pierced or pricked by the lancet, the user can then move their finger to the level of the plasma collection module 110 in order to deposit the blood drops 101 therein, as Figure 1 To do this, Figure 3 As shown in FIG. 1 , in a preferred embodiment, the module 110 includes a semipermeable membrane 111 through which the collected blood 101 can pass or flow. Thus, such a semipermeable membrane 111, such as the known and commercially available Pall's Vivid TM The brand allows separation of blood components according to their size. Thus, the semipermeable membrane 11 is arranged to receive a certain amount of blood 101 and separate the blood components according to their size by gravity when the semipermeable membrane 111 is substantially horizontal, so that white blood cells, red blood cells and other large diameter components can be trapped in the membrane 111, which is different from the plasma 102 that can flow through the membrane. Filtration efficiency percentages of the order of sixty percent or more are envisioned. Thus, when the membrane 111 is substantially horizontal, the plasma 102 can be collected below the membrane 111 by gravity.
[0025] Furthermore, in order to concentrate the blood 101 on the membrane 111 and avoid the blood 101 from spreading outside the separation / filtration surface defined by the edge of the membrane 111, the collection module 110 may include a membrane holder 112 positioned so as to squeeze and hold the edge of the membrane 111. However, a person skilled in the art will not be bound by such a membrane holding device 112 and will be able to envision any type of device that allows the described function to be achieved.
[0026] Once the plasma 102 is able to be separated from other blood components, it is necessary to be able to recover it to allow the continuity of the plasma 102 in the device 100 to be established. In this regard, the plasma 102 must be removed from the semipermeable membrane 111 and also transported to the capillary channel 120. The present invention is clearly distinguished from the teaching obtained from the document US2012 / 0275955A1, which adopts the presence of a vacuum chamber in order to generate a flow and forcibly separate plasma from a blood sample through a membrane. This forced filtration may deform the membrane, or even produce a phenomenon called hemolysis, according to which red blood cells may rupture under the action of the flow through the membrane, thereby degrading the obtained plasma. In fact, the cellular components (e.g., potassium, lactate dehydrogenase, hemoglobin) released during this destruction can reduce the relevance and accuracy of subsequent quantification of proteins based on the hemolyzed plasma. Unlike this technical teaching obtained from the document US2012 / 0275955A1, such as Figure 1 As shown in , the collection module 110 according to the present invention may include a specific surface 113, which is located upstream of the fluid connection of the plasma collection module 110 with the first end 120a of the capillary channel 120. This specific surface 113 makes it possible to extract the plasma 102 from the semipermeable membrane 111 by gravity and make it flow and advance by capillary action inside the device 100 to reach the capillary channel 120. Therefore, the present invention makes it possible to prevent any risk of hemolysis or deformation of the semipermeable membrane 111, preserve the plasma 102 thus separated, and therefore maintain any quantitative correlation related to the plasma 102.
[0027] In order to allow the establishment of continuity of the plasma 102 in the device 100 and not just to retain the plasma 102, in other words, to draw the plasma 102 from the specific surface 113 and passively move it in the capillary channel 120, the specific surface must have an optimized balance between hydrophobic and hydrophilic properties (i.e. the properties specified above in this specification).
[0028] In fact, due to the fact that the plasma 102 is mainly hydrophilic (about 90% of which is formed by water) but also contains hydrophobic substances, the specific surface 113 must have a suitable surface tension and be composed of a hydrophilic material without being water-soluble. Therefore, the specific surface 113 is arranged between the semipermeable membrane 111 and the first end 120a of the first capillary channel 120, and has determined hydrophobicity, hydrophilicity and surface tension properties, so as to extract the plasma 102 from the semipermeable membrane 111, and cause the plasma 102 to flow in the first capillary channel 120 or make the plasma 102 move in the first capillary channel 120.
[0029] In this regard, the specific surface 113 may preferably be composed of polymethyl methacrylate, a thermoplastic polymer abbreviated as PMMA, which has mainly hydrophilic properties (contact angle with water is of the order of sixty-eight degrees) and exhibits a good balance between hydrophobic groups (methylene groups) and hydrophilic groups (carbonyl groups). However, a person skilled in the art will not be bound by this material and will be able to envision any other type of material that makes it possible to obtain such properties or equivalents, such as polyacrylamide, polyurethane, poly(hydroxyethyl methacrylamide) or polyethylene glycol derivatives.
[0030] In a variant or in addition, the hydrophilic properties of the chosen material can be optimized or improved by means of a treatment that makes it possible to functionalize the surface of the material, in particular a treatment that modifies its surface tension, such as a gas plasma treatment (argon, oxygen, etc.), a corona treatment or even a chemical treatment (with sodium hydroxide, polyvinyl alcohol or hydroxypropyl methylcellulose, etc.).
[0031] Once step 210 is completed, the step consists of depositing the blood 101 or plasma 102 in the plasma collection module 110 so as to obtain the established continuity of the plasma 102 in the capillary channel 120 or to move the plasma 102 in the capillary channel 120, such as Figure 2 As shown in , the method 200 comprises a step 220 of filling the capillary channel 120 with plasma 102. Thus, this step 220 makes it possible to have a constant controlled volume of plasma 102 in the capillary channel 120, so that the amount of said plasma in the capillary channel 120 is perfectly regulated. To this end, the capillary channel 120 has determined dimensions, including a predefined length L, such as Figure 4.Shown in.Described length L corresponds to the length of the restriction between the fluid connection of described storage container 130 and capillary channel 120 and described second end of capillary channel 120.Therefore, for the cross-sectional diameter of given described capillary channel 120, described length L makes it possible to determine and control the amount of blood plasma 102 when being full of capillary channel 120 with blood plasma 102.As an example, for the blood plasma volume of ten to one hundred microliters of magnitude, capillary channel 120 can have the internal diameter basically included between 0.3 and 1.5 millimeters and the length L included between 15 and 80 millimeters.This capillary channel 120 can be made of glass, plastics, or by any other material with suitable characteristic (hydrophilic property, the property that promotes capillary action, electrostatic property and even mechanical property, for example elasticity) constitute.But, preferably, plastic material is advantageous, because its surface functionalization (especially making it possible to increase hydrophilicity and / or improve capillary action) is easier than other materials.In addition, this capillary channel 120 can be integrated in described device 100 with the form of complete element. However, in one variation, where the device 100 includes a flexible or rigid body (not shown in the figure for simplicity) housing components of the device 100 (e.g., a collection module 110, a capillary channel 120, a storage container 130, a mixing chamber 140), such components may be produced directly by molding or additive manufacturing the body or by removing material therefrom using laser or machining techniques.
[0032] Furthermore, in order to facilitate the filling of the capillary channel 120 with plasma 102, the volume of the capillary channel 120 may be dimensioned to be smaller than the volume of plasma 102 contained in the collection module 110. In a variant, the step 220 of filling the capillary channel 120 with plasma 102 may consist of waiting for a predetermined duration, which is defined according to the dimensions of the capillary channel 120, once the plasma 102 flows along the capillary channel 120. However, a person skilled in the art will not be bound by limiting the invention to such a step and will be able to envision any other way of implementing the filling step 220, for example, the appearance of a colored indicator when the capillary channel 120 is filled with plasma 102 or the use of an information item delivered by a sensor (e.g., an optical sensor) positioned proximate to the second end 120b of the channel 120.
[0033] In order to avoid any backflow or overflow, according to a first mode, the means 140 for preventing any fluid from returning to the collection module 110 may consist of a non-return valve. The latter thus allows the passage of the plasma 102 from the collection module 110 into the capillary channel 120 and prevents any backflow of the plasma 102 from the capillary channel 120 to the collection module 110.
[0034] exist Figure 5In another preferred embodiment shown in , such means 140 for preventing any return of fluid may consist of a screw, the stroke of which induces a "clamping" of said capillary channel 120. Once the filling of the capillary channel 120 with plasma 102 has been achieved, such a screw can thus be actuated so as to exert pressure on the capillary channel 120 so as to clamp and / or close it, thus making it possible to stop any flow of plasma 102 in the direction of the collecting module 110. When it is necessary to "close" said channel 120 at the level of its first end 120a, such a screw is actuated manually or motorized so that it can abut against the capillary channel 120.
[0035] However, the device 140 of other types that prevents any fluid from returning to the collection module 110 can be composed of, for example, a valve designed for use by / by not using, for which the valve is opened or closed according to the pressure of the fluid therein. The valve available on the market called a guillotine or through-valve can be mentioned. In addition, this valve can be manually actuated by the user themselves under the premise that the step 220 has been completed, but it can also be envisioned to make this actuation automatic. In the latter case, this device comprises a processing unit, such as a microprocessor, which is arranged to use the information derived from a sensor (the sensor is designed or positioned to detect the fullness of capillary channel 120) and produce a closing signal intended for an electric control valve. In a modification, it can be envisioned to use a clock, or be referred to as a timer, instead of using a sensor. Therefore, in the case of this hypothesis, a closing signal intended for an electric control valve can be sent based on a predetermined elapsed time.
[0036] It should be noted that since this device 140 for preventing any fluid return is positioned upstream of the fluid connection between the storage container 130 and the capillary channel 120 (i.e. substantially at the level of the first end 120a of the capillary channel 120), this also makes it possible to further ensure that the volume of plasma 102 contained in the portion of the capillary channel 120 defined by the length L is constant.
[0037] like Figure 2 and Figure 5, carry out step 230 (when this needs to be actuated in parallel with or after the actuation of the device 140 for preventing any fluid from returning) to induce the forced flow of reagent 103 in capillary channel 120, and described reagent 103 is contained in the storage container 130 of reagent 103 in advance.In this respect, this storage container 130 can be arranged in the form of a flexible bag (commonly referred to as " blister bag (blister pouch) ") intended to hold fluid, and described flexible bag is connected with capillary channel 120 fluids by, for example, forming a capillary of T-joint 120c with capillary channel 120.Therefore, in this embodiment, reagent 103 is contained in described flexible bag, and the forced flow of described reagent 103 in described passage 120 can be induced by the mechanical compression carried out by the user of described device 100.In other words, the user himself presses on flexible bag so that its content (reagent 103) is released thereinto in capillary channel 120.But those skilled in the art will not be constrained by the shape and / or design of this fluid storage container 130. Any other type of storage container can be used, such as a syringe actuated by a user, to replace the flexible bag. In a modification, such storage container 130 (flexible bag, syringe or any other type) can include an actuator 131, which is arranged to cause displacement or compression of a piston, thereby forcing the induction reagent 103 to flow into the capillary channel 120. Then step 230 will be composed of: (by the user) manually or in an automatic manner (to prevent any fluid from returning to the collection module 110 as with the above-mentioned electric control valve) control of this actuator 131. Optionally, the processing unit that generates the closing signal of the valve will also generate the control signal of this actuator 131.
[0038] Therefore, if Figure 5 Neutralization Figure 6As shown in , since the capillary channel 120 is filled with plasma 120, the forced flow of the reagent 103 in the channel 120 induces the flow of the plasma 102 and the reagent 103 contained in the capillary channel 120 until reaching the mixing chamber 150 which is fluidically connected to the second end 120b of the channel 120 (i.e., the lower part of the channel 120 in the illustrated embodiment example). In other words, this forced flow of the reagent 130 acts as a "fluid piston" to move the plasma 102 contained in the filled capillary channel 120 until reaching the mixing chamber 150, in which a homogenous mixture 104 of the plasma 102 and the reagent 130 will be obtained. In order to promote and facilitate the passive homogenization of the plasma-reagent mixture 104, the mixing chamber 150 may include a network 151 of channels arranged, for example, in a zigzag, serpentine or herringbone shape. A person skilled in the art will not be constrained by the design of the mixing chamber 150 that allows for a uniform fluid plasma-reagent mixture 104, since any other type of design or structure can be envisioned, for example, a structure known as a micro-pillar structure. In addition, such a mixing chamber 150 comprises an outlet 152 through which the constant uniform plasma-reagent mixture 104 can flow. Thus, such an outlet 152 corresponds to an ejection / evacuation outlet for the plasma-reagent mixture 104 to the outside of the device 100.
[0039] Furthermore, the dimensions of the microfluidic device 100 for obtaining a plasma-reagent mixture according to the present invention are set so that the volume of the storage container 130 is greater than the sum of the volumes of the capillary channel 120 and the mixing chamber 150. By way of illustration and not limitation, such a mixing chamber 150 may have a volume of sixty microliters (which can correspond to a dimension of four millimeters in diameter by five millimeters in length) to two hundred and fifty microliters (which can correspond to a dimension of five millimeters in diameter by thirteen millimeters in length), and the storage container 130 may have a volume of one hundred to three hundred microliters. Thus, the flow of the plasma 102 and the reagent 103 contained in the capillary channel 120 will occur until the chamber 150 is filled with the plasma-reagent mixture 104, thereby allowing a constant flow of the plasma-reagent mixture 104 via the outlet 152 of the mixing chamber 150. Therefore, taking into account the storage and transport functions of the device 100 according to the invention and the nature of the fluid intended to flow therein, the device 100 according to the invention is clearly distinguished in its structure and size from the blood transport devices disclosed in documents US2014 / 0309557 and WO 2014 / 172247A1. In fact, the known transport devices are arranged so that the blood sampled and stored during transportation between the sampling point and the analysis center is passively retained therein together with the stabilizer or anticoagulant. Only after the separation of plasma by centrifugal force performed by an item of third-party equipment, the plasma sample can be extracted from the transport device by an actuator, which is arranged to facilitate the extraction of the contained plasma via the outlet opening closed before this for analytical purposes. In the absence of a previous action of the centrifuge, the actuator of the known transport device will only make it possible to extract the blood stored in the blood sample transfer device.
[0040] By virtue of the innovative arrangement of the device 100 according to the invention, once the constant homogeneous plasma-reagent mixture 104 flows out of the outlet 152 of the mixing chamber 150, the method 200 according to the invention for implementing such a microfluidic device 100 for obtaining a homogeneous plasma-reagent mixture comprises a final step 240 of collecting the mixture 104. In a preferred mode of the invention, Figure 7 As shown in , such a step 240 may consist of positioning a reactive strip 160, such as a lateral flow immunoassay (LFI) strip, downstream of the outlet 152 of the mixing chamber 150. The mixture 104 may thus be deposited on the reactive strip 160.
[0041] Such reactive strip 160 can be used directly by the user to obtain quantification of the target blood biomarker by positioning the strip 160 in an optical reader, which allows the user to immediately read / display the quantitative results. Thus, individuals wishing to enhance health monitoring can utilize a system for quantifying blood biomarkers in their place of residence or on the move, the system comprising a microfluidic device 100 for obtaining a uniform plasma-reagent mixture according to the present invention, a reactive strip 160, and an optical reader. Such a system may include a device for wired or wireless communication with a remote computer entity to transmit quantitative results. Such a computer entity may consist of a mobile electronic object (a portable computer, a touch screen tablet, or a smart phone) that hosts a software application or appropriate computer program that makes it possible, for example, to record results and / or constitute a medical dashboard or history of the analyses performed.
[0042] Those skilled in the art will appreciate that the present disclosure is not limited to those specifically shown and described above. Without departing from the scope of the present invention as defined by the appended claims, other modifications may be envisioned. In particular, in the preferred examples described above, device 100 includes a capillary channel. However, in order to increase the capillary force applied to the plasma present in collection module 110, device 100 may include several capillary channels (two, three or even more), which on the one hand lead to collection module 110, and on the other hand lead to mixing chamber 150, optionally via a "parent" collection channel. In addition, capillary channels that are conducive to industrial use due to non-deformability have been mentioned in the present application. However, in a modification, capillaries may be used.
Claims
1. A microfluidic device (100) for obtaining a homogeneous plasma-reagent mixture, comprising: - a collection module (110) for blood (101); - a first capillary channel (120) having a first end (120a) fluidically connected to the collection module (110); - a fluid storage container (130) fluidically connected to the first capillary channel (120); a mixing chamber (150) fluidically connected to the second end (120b) of the first capillary channel (120), the mixing chamber being arranged to passively induce a homogeneous mixture (104) of the fluid originating from the first capillary and having an outflow outlet (152) for the homogeneous mixture; - means (140) for preventing any fluid from returning to said collection module (110); Features: - The collection module (110) comprises: o a semipermeable membrane (111) arranged to receive a volume of blood (101) and designed to separate blood components by gravity according to their size when the semipermeable membrane (111) is substantially horizontal and thereby retain said components except for plasma (102); a specific surface (113) disposed between the semipermeable membrane (111) and the first end (120a) of the first capillary channel (120) and having hydrophobicity, hydrophilicity and surface tension properties so as to extract the plasma (102) from the semipermeable membrane (111) and cause the plasma (102) to flow in the first capillary channel (120); - the first capillary channel (120) has a determined dimension (L) between the fluid connection of the storage container (130) with the first capillary channel (120) and the second end (120b) of the first capillary channel (120) in order to control the amount of plasma (102) when the first capillary channel (120) is filled with plasma (102); - the fluid contained in the storage container is a reagent (103) intended to be mixed with the plasma; - The storage container (130) is arranged as follows: ○ The contained reagent volume (130) is greater than the sum of the fluid volumes that can be contained in the first capillary channel (120) and the mixing chamber (150); ○ Having an actuator (131), which is designed to induce forced flow of the reagent (103) in the first capillary channel (120) when the actuator is controlled after the first capillary channel is filled with plasma (102), driving the uniform plasma-reagent mixture (104) to flow through the outflow port (152) of the mixing chamber (150).
2. A microfluidic device (100) for obtaining a uniform plasma-reagent mixture according to one of the preceding claims, wherein the first end (120a) of the first capillary channel (120) is positioned substantially at the center of the plasma collection module (110).
3. A microfluidic device (100) for obtaining a homogeneous plasma-reagent mixture according to any one of the preceding claims, wherein the collection module (110) comprises a membrane holder (112) arranged to concentrate the blood (101) on the semipermeable membrane (111).
4. A microfluidic device (100) for obtaining a homogeneous plasma-reagent mixture according to any of the preceding claims, wherein the specific surface (113) is composed of polymethyl methacrylate, a thermoplastic polymer, polyacrylamide, polyurethane, poly(hydroxyethyl acrylamide) or a polyethylene glycol derivative.
5. A microfluidic device (100) for obtaining a uniform plasma-reagent mixture according to any of the preceding claims, wherein the mixing chamber (150) comprises a network (151) of channels each arranged in a zigzag, serpentine or herringbone shape to passively induce the uniform plasma-reagent mixture (104).
6. A method (200) for implementing a microfluidic device (100) for obtaining a homogeneous plasma-reagent mixture arranged according to any one of the preceding claims, the method comprising: - a step (210) of depositing blood (101) or plasma (102) on the semipermeable membrane (111) of the plasma collection module (110) when the device is positioned so that the semipermeable membrane (111) is horizontal; - a step (220) of filling the first capillary channel (120) with plasma (102); - after the step of filling the first capillary channel (120) with plasma (102), a step (230) of controlling the actuator (131) of the storage container (130) to induce the reagent (103) previously contained in the storage container (130) to forcibly flow into the first capillary channel (120) after the mixing chamber (150) is filled; - A step (240) of collecting the homogenous plasma-reagent mixture (104) from the outflow outlet (152) of the mixing chamber (150).
7. The method (200) for implementing the microfluidic device (100) for obtaining a homogeneous plasma-reagent mixture according to the preceding claim, wherein the step (220) of filling the first capillary channel (120) with plasma (102) consists of: Once the plasma (102) flows into the first capillary channel (120), a predetermined duration is waited, the duration being a function of the dimensions of the first capillary channel (120).
8. The method (200) for obtaining a uniform plasma-reagent mixture using a microfluidic device (100) according to any one of claims 6 and 7, wherein the step (240) of collecting the uniform plasma-reagent mixture (104) consists of: A reactive strip (160) is positioned downstream of the outlet (152) of the mixing chamber (150) such that the strip (160) collects all or a portion of the homogenous plasma-reagent mixture (104).
Citation Information
Patent Citations
A plasma separating microfluidic device
CN107923905A
Microfluidic structure for plasma separation and detection
CN111644216A
Mask for deposition, method of fabricating the same, and method of manufacturing for display device using the mask for deposition
KR1020210032586A
Automatic plasma separation and metering
US20180207638A1
Cardiac Biomarker Assay Cartridge or Card
US20190283025A1
